Takeda

News

BioNTech and Takeda add new ADCs to their pipelines

A pair of licensing deals today for BioNTech and Takeda provide further examples that antibody-drug conjugates (ADCs) are cementing their place as in the biopharma armamen

News

Hutchmed files Takeda-partnered colorectal cancer drug in US

Chinese biotech Hutchmed has completed its rolling marketing application in the US for oral VEGF receptor inhibitor fruquintinib, which was licensed by Takeda for a hefty

Patients

Challenges and opportunities with plasma-derived therapies

This newest pharmaphorum podcast welcomes Takeda's Dr Kristina Allikmets.

News

Chasing BMS, Takeda trumpets TYK2 data in psoriasis

Pharma group is hoping for big things, after splashing out $4bn upfront for the drug last year.

News

Phase 3 trial win sets up rare disease drug filing for CSL

VANUGUARD trial of garadacimab in HAE sets up a pursuit of Takeda's fast-growing Takhyzro.

News

Takeda grabs ex-China fruquintinib rights from Hutchmed

Chinese biotech Hutchmed's push to sign partnerships for its drug products outside its home market has resulted in a $1.13 billion deal with Japan's Takeda, including a hefty upfront fee of

BioNTech and Takeda add new ADCs to their pipelines

Hutchmed files Takeda-partnered colorectal cancer drug in US

Challenges and opportunities with plasma-derived therapies

Chasing BMS, Takeda trumpets TYK2 data in psoriasis

Phase 3 trial win sets up rare disease drug filing for CSL

Takeda grabs ex-China fruquintinib rights from Hutchmed

CHMP decision levels the playing field for GSK's RSV jab

How to meet your physicians where they are online

Takeda

Editor's Picks